STAT+: FDA Slams Soon-Shiong and ImmunityBio for Making ‘False and Misleading’ Claims About a Drug

Why It Matters

Misleading promotion threatens patient safety and can distort market valuations, prompting stricter regulatory scrutiny across the oncology sector.

Key Takeaways

• FDA issued warning letter to ImmunityBio for false claims.
• Anktiva approved only with BCG vaccine, not solo therapy.
• Ads claimed “cancer‑free” outcomes unsupported by trials.
• Risks and side effects were omitted from promotional material.
• Enforcement may affect Soon‑Shiong’s market reputation and stock.

Pulse Analysis

The Food and Drug Administration’s March 13 warning letter to ImmunityBio underscores the agency’s zero‑tolerance stance on deceptive drug promotion. Patrick Soon‑Shiong, a serial entrepreneur behind companies such as NantWorks, has long courted media attention, but the FDA’s reprimand signals that hype cannot replace evidence. Anktiva, the company’s checkpoint‑inhibitor approved for high‑risk non‑muscle‑invasive bladder cancer, was portrayed in television spots and a podcast as a universal cancer cure. Such overstatements jeopardize patient trust and invite costly enforcement actions.

Clinical trials for Anktiva demonstrate modest recurrence‑free survival benefits when paired with the Bacillus Calmette‑Guérin (BCG) vaccine, not a standalone miracle drug. The FDA noted the ads omitted this mandatory combination and downplayed serious adverse events like cystitis and fever. By claiming patients become ‘cancer‑free,’ the marketing material contradicted trial endpoints that measured only disease‑free intervals. Investors and insurers now face heightened scrutiny, as exaggerated efficacy claims can inflate stock valuations and trigger reimbursement challenges.

The episode serves as a cautionary tale for biotech firms navigating the fine line between promotion and misinformation. Regulators are increasingly deploying digital monitoring tools to flag non‑compliant content across podcasts, social media, and traditional broadcasts. Companies that prioritize transparent communication not only avoid fines but also strengthen long‑term brand credibility in a crowded oncology market. As the FDA tightens oversight, stakeholders—from clinicians to venture capitalists—must demand rigorous evidence before endorsing breakthrough‑sounding narratives.